Oncolytics Biotech Inc ONCY

PanCAN 2nd annual Therapeutic Accelerator Award Goes to ONCY

[Noteable]

PanCAN continues to accelerate new treatment options for patients with pancreatic cancer through the announcement of a $5 million grant to a biotechnology company at the leading edge of drug development.

The recipient of PanCAN’s second annual Therapeutic Accelerator Award, Oncolytics Biotech® Inc., was chosen through a rigorous review process for its promising work on an investigational treatment combination that uses an oncolytic virus called pelareorep to activate the body’s immune system to kill off pancreatic cancer cells. Clinical data has shown the treatment combination results in the recruitment and activation of cancer-fighting immune cells, including natural killer cells, dendritic cells, and T-cells, leading to a robust immune response focused specifically on cancer cells while sparing healthy cells.

https://pancan.org/news/pancans-5-million-therapeutic-accelerator-award-goes-to-oncolytics-biotech-inc/

[Noteable]

Through the proposed clinical trial, the investigational virus pelareorep would be intravenously administered in patients with metastatic pancreatic cancer who have not received prior treatment, in combination with modified FOLFIRINOX chemotherapy and an immune checkpoint inhibitor, which is a class of drugs that releases the “brakes” on the immune system so that the tumor can’t protect

[pelaboost]

@Notebook. In the 9/26 release it was stated  -  pela plus modified Folfirinox with or without a CPI. Implying 2 combos? I would doubt that has changed, unless a decision has been take for CPI plus pela plus Folfirinox solely. Does the modified Folfirinox get only a CPI and pela or are they going with and without. A key piece of  knowledge. TIA

[Noteable]

pelaboost as per PanCan  - The Therapeutic Accelerator Award enables the next phase of research for this exciting work by funding an early-phase clinical trial testing the investigational treatment combination: Oncolytics’ proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor. If the results are encouraging, the

[Noteable]

Implies a two arm study.